期刊
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
卷 9, 期 3, 页码 429-439出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2016.1133288
关键词
therapeutic drug monitoring; golimumab; Inflammatory bowel disease; adalimumab; infliximab; loss of response; anti-tumor necrosis factor antibodies
资金
- AbbVie
- Merck Sharp Dohme
- Achmea healthcare
- ZonMW
- Ferring
- Jansen Biologics
- Merck Sharp Dome
- Mundipharma
- Norgine
- Shire
- Takeda
- Tillotts
- UCB
- Vifor
After the introduction of anti-tumor necrosis factor (anti-TNF) agents, the clinical outcome of patients with Inflammatory Bowel Disease (IBD) has improved significantly. However, use of anti-TNF therapy is complicated by loss of response. In order to maintain remission, adequate serum levels are required. Hence, therapeutic drug monitoring (TDM) is important in order to optimize serum drug levels, especially in patients with loss of response to these agents. Optimization of anti-TNF therapy by applying TDM enables clinicians to regain response to TNF blockers in a significant proportion of patients. It is important to use anti-TNF agents in their most optimal way, since these therapeutic agents are expensive and the medical options after failing anti-TNF therapy are limited. Here, we will discuss how to optimize treatment with anti-TNF agents in IBD patients in order to improve treatment efficacy, prevent anti-drug antibody formation, reduce side effects, discontinue unnecessary treatment and manage costs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据